The Experts below are selected from a list of 120 Experts worldwide ranked by ideXlab platform
Seiichi Takasaki - One of the best experts on this subject based on the ideXlab platform.
-
Structural study of N-linked sugar chains of Sheep Erythrocyte membrane glycoproteins
Glycoconjugate Journal, 1998Co-Authors: Kaoru Kusui, Seiichi TakasakiAbstract:Our previous study showed that non-reducing terminal galactose residues of N-linked sugar chains present in Sheep Erythrocyte membrane glycoproteins are important for rosette formation with T lymphoblastic cells [Ogasawara et al. (1995) Immunol Lett 48: 35–38]. As a first step to elucidate the significant structures of sugar chains involved in rosette formation, we analysed N-linked sugar chains released from the membrane glycoproteins by hydrazinolysis. The oligosaccharides were labeled with NaB3H4 and fractionated using columns of Aleuria aurantia lectin-Sepharose, MonoQ and Bio-Gel P-4. Structural analyses of oligosaccharides by sequential exoglycosidase digestion in combination with methylation analysis revealed that the membrane glycoproteins contain bi- (19%), tri- (33%), and tetraantennary (44%) complex-type oligosaccharides and that the oligosaccharides having exposed galactose residues amount to 40% of the total.
-
analysis of o linked oligosaccharide alditols by high ph anion exchange chromatography with pulsed amperometric detection
Analytical Biochemistry, 1997Co-Authors: Norihiro Kotani, Seiichi TakasakiAbstract:Abstract To apply high-pH anion exchange chromatography with pulsed amperometric detection (HPAEC-PAD) to the accurate and sensitive analysis of O-linked oligosaccharide alditol, removal of glycopeptides and peptides from oligosaccharide samples obtained by β-elimination was first investigated. The results obtained by using fetuin as a model glycoprotein indicated that (glyco)peptides derivatized by fluorescamine are easily removed from the β-eliminated oligosaccharide sample by means of a Sep-Pak C18 cartridge due to their increased hydrophobicity. This clean-up procedure was also effectively applied to the β-eliminated oligosaccharide sample obtained from delipidated Sheep Erythrocyte ghosts. Furthermore, structural analysis of the oligosaccharide alditols by HPAEC-PAD was successfully performed in combination with partial and complete desialylation, composition analysis, periodate oxidation, and glycosidase digestion and revealed that Sheep Erythrocyte membrane glycoproteins contain Galβ1 → 3GalNAc and Galβ1 → 4GlcNAcβ1 → 3Galβ1 → 3GalNAc, to which one or two residues of Neu5Ac and Neu5Gc are attached in different combinations.
-
role of terminal galactose residues in n linked sugar chains of Sheep Erythrocyte membrane glycoproteins in rosette formation with t lymphocytes
Immunology Letters, 1995Co-Authors: Hiroyuki Ogasawara, Kaoru Kusui, Seiichi TakasakiAbstract:Abstract In this study, we found that rosette formation of T lymphoblastic Molt-3 cells with Sheep Erythrocytes is inhibited by addition of membrane glycoproteins which were solubilized from Sheep Erythrocyte ghosts by the lithium diiodosalicylate extraction methods. Their rosetting inhibitory activity was markedly reduced by digestion with N -glycanase, but not with O -glycanase. The inhibitory activity was also reduced by β-galactosidase digestion, while it was enhanced by desialylation. These observations indicate that nonreducing terminal galactose residues of N -linked sugar chains included in membrane glycoproteins on Sheep Erythrocytes are important for rosette formation with T lymphocytes.
Kaoru Kusui - One of the best experts on this subject based on the ideXlab platform.
-
Structural study of N-linked sugar chains of Sheep Erythrocyte membrane glycoproteins
Glycoconjugate Journal, 1998Co-Authors: Kaoru Kusui, Seiichi TakasakiAbstract:Our previous study showed that non-reducing terminal galactose residues of N-linked sugar chains present in Sheep Erythrocyte membrane glycoproteins are important for rosette formation with T lymphoblastic cells [Ogasawara et al. (1995) Immunol Lett 48: 35–38]. As a first step to elucidate the significant structures of sugar chains involved in rosette formation, we analysed N-linked sugar chains released from the membrane glycoproteins by hydrazinolysis. The oligosaccharides were labeled with NaB3H4 and fractionated using columns of Aleuria aurantia lectin-Sepharose, MonoQ and Bio-Gel P-4. Structural analyses of oligosaccharides by sequential exoglycosidase digestion in combination with methylation analysis revealed that the membrane glycoproteins contain bi- (19%), tri- (33%), and tetraantennary (44%) complex-type oligosaccharides and that the oligosaccharides having exposed galactose residues amount to 40% of the total.
-
role of terminal galactose residues in n linked sugar chains of Sheep Erythrocyte membrane glycoproteins in rosette formation with t lymphocytes
Immunology Letters, 1995Co-Authors: Hiroyuki Ogasawara, Kaoru Kusui, Seiichi TakasakiAbstract:Abstract In this study, we found that rosette formation of T lymphoblastic Molt-3 cells with Sheep Erythrocytes is inhibited by addition of membrane glycoproteins which were solubilized from Sheep Erythrocyte ghosts by the lithium diiodosalicylate extraction methods. Their rosetting inhibitory activity was markedly reduced by digestion with N -glycanase, but not with O -glycanase. The inhibitory activity was also reduced by β-galactosidase digestion, while it was enhanced by desialylation. These observations indicate that nonreducing terminal galactose residues of N -linked sugar chains included in membrane glycoproteins on Sheep Erythrocytes are important for rosette formation with T lymphocytes.
Marcel R M Van Den Brink - One of the best experts on this subject based on the ideXlab platform.
-
t cell depleted unrelated donor stem cell transplantation provides favorable disease free survival for adults with hematologic malignancies
Biology of Blood and Marrow Transplantation, 2011Co-Authors: Ann A Jakubowski, Trudy N Small, Nancy A Kernan, Hugo Castromalaspina, Nancy H Collins, Guenther Koehne, Katharine C Hsu, Miguel Perales, Genovefa A Papanicolaou, Marcel R M Van Den BrinkAbstract:We report a prospective phase II clinical trial in 35 adult patients (median age 40.5 years) with hematologic malignancies who received T cell–depleted, hematopoietic stem cell transplants from HLA-compatible, unrelated donors. The cytoreductive regimen consisted of hyperfractionated total-body irradiation, thiotepa, and fludarabine. The preferred graft source was granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood stem cells (PBSC). PBSC were CD34+ selected, followed by Sheep Erythrocyte rosetting to deplete residual T cells. Anti-thymocyte globulin provided graft rejection prophylaxis. No additional graft-versus-host disease (GVHD) prophylaxis was planned. Estimated disease-free survival at 4 years is 56.8% for the entire group and 75% in patients with standard-risk disease. The cumulative incidence of relapse is 6%. Acute GVHD grade II-III developed in 9% and chronic GVHD in 29% of patients. Fatal infections occurred in 5 of 35 (14%) patients. There was 1 late graft failure. This study demonstrates durable engraftment with a low overall incidence of GVHD. Its curative potential is reflected in the remarkably low relapse rate at 4 years.
F E Ward - One of the best experts on this subject based on the ideXlab platform.
-
hematopoietic stem cell transplantation for the treatment of severe combined immunodeficiency
The New England Journal of Medicine, 1999Co-Authors: Rebecca H. Buckley, Sherrie E. Schiff, Richard I. Schiff, Louise M Markert, Larry W Williams, Joseph L Roberts, Laurie Myers, F E WardAbstract:Background Since 1968 it has been known that bone marrow transplantation can ameliorate severe combined immunodeficiency, but data on the long-term efficacy of this treatment are limited. We prospectively studied immunologic function in 89 consecutive infants with severe combined immunodeficiency who received hematopoietic stem-cell transplants at Duke University Medical Center between May 1982 and September 1998. Methods Serum immunoglobulin levels and lymphocyte phenotypes and function were assessed and genetic analyses performed according to standard methods. Bone marrow was depleted of T cells by agglutination with soybean lectin and by Sheep-Erythrocyte rosetting before transplantation. Results Seventy-seven of the infants received T-cell–depleted, HLA-haploidentical parental marrow, and 12 received HLA-identical marrow from a related donor; 3 of the recipients of haploidentical marrow also received placental-blood transplants from unrelated donors. Except for two patients who received placental bloo...
Ann A Jakubowski - One of the best experts on this subject based on the ideXlab platform.
-
t cell depleted unrelated donor stem cell transplantation provides favorable disease free survival for adults with hematologic malignancies
Biology of Blood and Marrow Transplantation, 2011Co-Authors: Ann A Jakubowski, Trudy N Small, Nancy A Kernan, Hugo Castromalaspina, Nancy H Collins, Guenther Koehne, Katharine C Hsu, Miguel Perales, Genovefa A Papanicolaou, Marcel R M Van Den BrinkAbstract:We report a prospective phase II clinical trial in 35 adult patients (median age 40.5 years) with hematologic malignancies who received T cell–depleted, hematopoietic stem cell transplants from HLA-compatible, unrelated donors. The cytoreductive regimen consisted of hyperfractionated total-body irradiation, thiotepa, and fludarabine. The preferred graft source was granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood stem cells (PBSC). PBSC were CD34+ selected, followed by Sheep Erythrocyte rosetting to deplete residual T cells. Anti-thymocyte globulin provided graft rejection prophylaxis. No additional graft-versus-host disease (GVHD) prophylaxis was planned. Estimated disease-free survival at 4 years is 56.8% for the entire group and 75% in patients with standard-risk disease. The cumulative incidence of relapse is 6%. Acute GVHD grade II-III developed in 9% and chronic GVHD in 29% of patients. Fatal infections occurred in 5 of 35 (14%) patients. There was 1 late graft failure. This study demonstrates durable engraftment with a low overall incidence of GVHD. Its curative potential is reflected in the remarkably low relapse rate at 4 years.
